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Improving Patient-Centered Outcomes through
Methodological Rigor
Timothy J. O’LearyFrom the Ofﬁce of Research and Development Veterans Health Administration, Washington, DC (Editor in Chief)Although the medical community is highly dependent
on published medical literature for assessing the accuracy
and utility of molecular diagnostics, individual publications
vary widely in the degree to which they include critical
features of study design such as nature of the study pop-
ulation, the choice of reference standards, choice of statistical
methods, and reporting of results. The use of differing design
features such as these often is entirely appropriate, since
studies that vary in these choices can inform medical
professionals who perform these tests in a variety of clinical
contexts.
The Patient Centered Outcomes Research Institute
(PCORI) recently published a draft methodology report1
that suggests that studies of diagnostic tests should clearly
specify clinical context and key elements of study design
(which should be informed by the clinical context of
testing), assess the effect of factors known to affect diag-
nostic performance and outcomes (such as threshold for
reporting a positive result), give preference to prospective
randomized designs (as opposed to observational studies),
use appropriate statistical techniques to address confounding,
and use structured reporting of diagnostic study results.
Universal implementation of these recommendations in the
short term is probably unrealistic, however. Randomized
clinical trials are extremely expensive to undertake, and
complete understanding of factors that may confound the
interpretation of a diagnostic test would seem to require
omniscience. Nevertheless, it is possible for The Journal
of Molecular Diagnostics to advance the PCORI goals
by identiﬁcation of individual papers that clearly meet
the criteria set forth by the Standards for Reporting of
Diagnostic Accuracy (STARD) initiative.2e4 These criteria
have been enumerated in a checklist that addresses each
element of a scientiﬁc paper and facilitates the description of
key elements such as study aims, characteristics of human
subjects and specimens, test methods, statistical evaluation,
and results reporting. Further advancement of the PCORICopyright ª 2013 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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http://dx.doi.org/10.1016/j.jmoldx.2012.11.001goals can be achieved by increasing the availability of data
and computer code used in attaining the reported results.
Beginning in 2013, the JMD will begin to annotate
papers that meet the STARD criteria with a footnote on
the title page. Authors who wish their papers to receive this
designation may submit a checklist that will form the basis
for evaluation by the editorial staff at the time of acceptance.
Participation is entirely voluntary, and the decision to
participate will not directly affect the process by which we
evaluate submitted papers. Authors should note, however,
that some of the STARD criteria (such as calculation of
95% conﬁdence intervals) are, and will remain, criteria for
scientiﬁc evaluation. The Journal hopes that by adopting the
STARD criteria in this way we can improve the commu-
nication between authors and readers.
Baggerly and Coombes5 have observed that the lack of
transparency in omics studies has resulted in the initiation of
clinical trials based on faulty conclusions and possible patient
endangerment. They suggested that risk would be ameliorated
were raw data and computer code publically available.
Although the JMD has considered requiring the deposit of
computer code and data as a prerequisite to publication, we
believe that such a requirement, were it widely adopted, would
discourage authors with a legitimate proprietary interest from
submitting their omics studies to high quality peer-reviewed
journals. For this reason, also beginning in 2013, we will
allow authors to annotate papers for which they agree to make
data and code available to qualiﬁed investigators for aminimum
of ﬁve years following publication. Although the Journal
encourages authors tomake thesematerials available in a public
form, asdescribed in the Instructions forAuthors,we realize that
in some cases access should result from a formal agreement,
such as a Data Use Agreement. Once again, the decision to
annotate an article to indicate the intention of authors to make
raw data and code available to readers is voluntary.
Although participation in the annotation programs is
voluntary, reviewers and editors may decide that for an
Editorialindividual paper, one or more of the elements is necessary
for the paper to be publishable. The creation of these
opportunities for voluntary annotation does not represent
a change in editorial policy and will not be used to restrict
reviewer discretion in the evaluation of submissions. The
Journal of Molecular Diagnostics encourages authors to
participate in these annotation programs, which reﬂect the
strong commitment of the Journal’s Editors, the Editorial
Board, and Editorial Ofﬁce staff to continual improvement
of the Journal’s scientiﬁc quality and utility to its readers.
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